<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010374</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN 20-0000-0009</org_study_id>
    <nct_id>NCT00010374</nct_id>
  </id_info>
  <brief_title>Electrical Activation of The Diaphragm for Ventilatory Assist</brief_title>
  <official_title>Multi-Center Pivotal Study of NeuRx RA/4 Ventilatory Assist Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synapse Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shepherd Center, Atlanta GA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Synapse Biomedical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      The objectives of this study are to test the Diaphragm Pacing Stimulation (DPS) System for
      treating chronic ventilatory insufficiency in persons with respiratory muscle paralysis. The
      hypothesis being tested in the clinical trial is that laparoscopic stimulation of the
      diaphragm at the motor point with intramuscular electrodes is safe and effective in providing
      significant ventilatory support to individuals who are otherwise dependant on a mechanical
      ventilator. Patients in our initial study group have all suffered from high-level spinal cord
      injury and were full-time dependant on positive pressure mechanical ventilation prior to
      inclusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      System: NeuRx RA/4 Diaphragm Pacing Stimulation System

      Summary:

      The NeuRx-RA/4 is intended to be used by individuals that have sustained a spinal cord
      injury, requiring aid with respiration. The device connects to the diaphragm which delivers
      current to stimulate muscle contractions to aid in respirations.

      This device currently holds an Investigational Device Exemption No. G920162 in the United
      States and is currently undergoing clinical trials at University Hospitals (Cleveland),
      Shepherd Center (Atlanta) and Vancouver (Canada).

      Introduction:

      The purpose of the study is to determine if a new, investigational diaphragm pacing system
      can provide part or full time respiratory support to spinal cord injured persons who normally
      need a mechanical ventilator. Patients with high-level spinal cord injuries typically
      experience chronic ventilatory insufficiency due to respiratory muscle paralysis; these
      patients must be supported predominantly through positive pressure mechanical ventilation
      with a ventilator.

      The diaphragm pacing system (NeuRx-RA/4) provides an electrical signal to the motor point of
      the muscle that causes the diaphragm to contract and allows patients to breathe more
      naturally.

      Synapse Biomedical, in conjunction with Case Western Reserve University and University
      Hospitals of Cleveland, are evaluating activating the diaphragm with percutaneous
      intramuscular electrodes implanted laparoscopically. This eliminates any direct contact with
      the phrenic nerve, allows all circuitry and electronics to remain outside the body, and
      provides direct, selective activation to each hemidiaphragm.

      The NeuRx RA/4 Diaphragm Pacing Stimulation (DPS) System has been implanted in 49 individuals
      with high-level spinal cord injury, resulting in over 20 years of cumulative active
      implantation time. The longest term patient was implanted March 6, 2000 and has been using
      the DPS System as his sole means of respiratory support for over five years. With the
      exception of the second patient, who does not meet our revised inclusion criteria and has
      gained no benefit from the implant, all of the remaining patients have been able to achieve
      significant tidal volumes with the DPS System. Based on the current results, the NeuRx RA/4
      DPS System has demonstrated safety and efficacy in patients with high-level spinal cord
      injury.

      Given the results to date the study has demonstrated preliminary efficacy in this patient
      population. With no unexpected significant adverse events reported the NeuRx RA/4 DPS System
      has performed reliably and safely in this patient population.

      Device Description: The NeuRx RA/4 Respiratory System is manufactured by Synapse Biomedical.
      The NeuRx RA/4 System comprises the following components: an external, battery powered
      Stimulator Device, an associated Programmer/Controller, Intramuscular Electrodes, associated
      percutaneous Lead Wires, a Surgical Placement Tool Set, and a surgical Mapping Station.

      Inclusion Criteria:

        -  Age 18 years or older

        -  Cervical spinal cord injury dependent on mechanical ventilation

        -  Clinically stable following acute spinal cord injury

        -  Bilateral phrenic nerve function clinically acceptable as demonstrated with EMG
           recordings and nerve conduction times

        -  Diaphragm movement with stimulation visible under fluoroscopy

        -  Clinically acceptable oxygenation on room air (&gt;90%)

        -  Hemodynamically stable

        -  No medical co-morbidities that would interfere with the proper placement or function of
           the device

        -  Committed primary caregiver

        -  Negative pregnancy test in females of child-bearing potential

        -  Informed consent from patient or designated representative

      Exclusion Criteria:

        -  Co-morbid medical conditions that preclude surgery

        -  Active lung disease (obstructive, restrictive or membrane diseases)

        -  Active cardiovascular disease

        -  Active brain disease

        -  Hemodynamic instability or low oxygen levels on room air

        -  Hospitalization for or a treated active infection within the last 3 months

        -  Significant scoliosis or chest deformity

        -  Marked obesity

        -  Anticipated poor compliance with protocol by either patient or primary caregiver.

        -  Currently breastfeeding
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enrolled Subjects Achieve Clinically Acceptable Tidal Volume Sustained Over a Continuous 4 Hour Period.</measure>
    <time_frame>Within one year after implantation</time_frame>
    <description>Number of enrolled subjects that successfully maintained clinically acceptable tidal volumes greater than basal requirements over a continuous 4 hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieve Clinically Acceptable Basal Metabolic Requirement of Tidal Volume Measured in ml During Chronic Stimulation.</measure>
    <time_frame>Within one year after implantation</time_frame>
    <description>To evaluate the ability of NeuRx DPS therapy to replace mechanical ventilation for patients on a chronic use basis, a secondary indicator of this objective is tidal volume (Vt) measured in ml during chronic stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Use NeuRx DPS to Breathe Without the Assistance of a Mechanical Ventilator for 24 Continuous Hours a Day</measure>
    <time_frame>Within one year of implantation</time_frame>
    <description>Number of patients that can achieve at least 24 hours daily use of the NeuRx DPS without the assistance of a mechanical ventilator.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Spinal Cord Injury</condition>
  <condition>Quadriplegia</condition>
  <arm_group>
    <arm_group_label>NeuRx DPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuRx DPS</intervention_name>
    <description>Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.</description>
    <arm_group_label>NeuRx DPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Cervical spinal cord injury dependent on mechanical ventilation

          -  Clinically stable following acute spinal cord injury

          -  Bilateral phrenic nerve function clinically acceptable as demonstrated with EMG
             recordings and nerve conduction times

          -  Diaphragm movement with stimulation visible under fluoroscopy

          -  Clinically acceptable oxygenation on room air (&gt;90%)

          -  Hemodynamically stable

          -  No medical co-morbidities that would interfere with the proper placement or function
             of the device

          -  Committed primary caregiver

          -  Negative pregnancy test in females of child-bearing potential

          -  Informed consent from patient or designated representative

        Exclusion Criteria:

          -  Co-morbid medical conditions that preclude surgery

          -  Active lung disease (obstructive, restrictive or membrane diseases)

          -  Active cardiovascular disease

          -  Active brain disease

          -  Hemodynamic instability or low oxygen levels on room air

          -  Hospitalization for or a treated active infection within the last 3 months

          -  Significant scoliosis or chest deformity

          -  Marked obesity

          -  Anticipated poor compliance with protocol by either patient or primary caregiver

          -  Currently breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Onders, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Craig Hospital</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113-2811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shepherd Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309-1465</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver CoastHealth</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>February 1, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2001</study_first_posted>
  <results_first_submitted>September 3, 2019</results_first_submitted>
  <results_first_submitted_qc>June 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2020</results_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diaphragm for Ventilatory Assist</keyword>
  <keyword>environmental/toxic disorders</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Quadriplegia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled patients who have suffered from high-level spinal cord injury, are full-time dependent on positive pressure mechanical ventilation and have intact bilateral phrenic nerves.</recruitment_details>
      <pre_assignment_details>One participant had a false positive phrenic nerve test after consent</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53">One compassionate use participant was withheld from analysis per FDA instructions</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>False positive phrenic nerve test</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with stable, high spinal cord injuries with stimulatable diaphragms, but lack control of their diaphragms that were implanted with the NeuRx DPS electrodes and able to condition their diaphragm using the study device.</population>
      <group_list>
        <group group_id="B1">
          <title>NeuRx DPS</title>
          <description>Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.
NeuRx DPS: Laparoscopic implantation of diprapagm electrode and subsequent pacing with the NeuRx DPS.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iceland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since injury</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.425" spread="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Enrolled Subjects Achieve Clinically Acceptable Tidal Volume Sustained Over a Continuous 4 Hour Period.</title>
        <description>Number of enrolled subjects that successfully maintained clinically acceptable tidal volumes greater than basal requirements over a continuous 4 hour period.</description>
        <time_frame>Within one year after implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.</description>
          </group>
        </group_list>
        <measure>
          <title>Enrolled Subjects Achieve Clinically Acceptable Tidal Volume Sustained Over a Continuous 4 Hour Period.</title>
          <description>Number of enrolled subjects that successfully maintained clinically acceptable tidal volumes greater than basal requirements over a continuous 4 hour period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success: Vt&gt;Basal Req. Continuous use &gt; 4 hours</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial success: Vt&gt;Basal Req. max use &lt; 4 hours</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Performance goal of 35%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Exact two-sided binomial test</method>
            <param_type>Exact two-sided binomial test</param_type>
            <param_value>96.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.0</ci_lower_limit>
            <ci_upper_limit>99.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achieve Clinically Acceptable Basal Metabolic Requirement of Tidal Volume Measured in ml During Chronic Stimulation.</title>
        <description>To evaluate the ability of NeuRx DPS therapy to replace mechanical ventilation for patients on a chronic use basis, a secondary indicator of this objective is tidal volume (Vt) measured in ml during chronic stimulation.</description>
        <time_frame>Within one year after implantation</time_frame>
        <population>Participants with high level spinal cord injury that are dependent on mechanical ventilation and have intact phrenic nerves.</population>
        <group_list>
          <group group_id="O1">
            <title>NeuRx Implanted Patients</title>
            <description>SCI patients who received NeuRx DPS implants</description>
          </group>
        </group_list>
        <measure>
          <title>Achieve Clinically Acceptable Basal Metabolic Requirement of Tidal Volume Measured in ml During Chronic Stimulation.</title>
          <description>To evaluate the ability of NeuRx DPS therapy to replace mechanical ventilation for patients on a chronic use basis, a secondary indicator of this objective is tidal volume (Vt) measured in ml during chronic stimulation.</description>
          <population>Participants with high level spinal cord injury that are dependent on mechanical ventilation and have intact phrenic nerves.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="745.6" spread="217.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Use NeuRx DPS to Breathe Without the Assistance of a Mechanical Ventilator for 24 Continuous Hours a Day</title>
        <description>Number of patients that can achieve at least 24 hours daily use of the NeuRx DPS without the assistance of a mechanical ventilator.</description>
        <time_frame>Within one year of implantation</time_frame>
        <population>Participants with high level spinal cord injury that are dependent on mechanical ventilation and have intact phrenic nerves.</population>
        <group_list>
          <group group_id="O1">
            <title>NeuRx Implanted Patients</title>
            <description>SCI patients who received NeuRx DPS implants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Use NeuRx DPS to Breathe Without the Assistance of a Mechanical Ventilator for 24 Continuous Hours a Day</title>
          <description>Number of patients that can achieve at least 24 hours daily use of the NeuRx DPS without the assistance of a mechanical ventilator.</description>
          <population>Participants with high level spinal cord injury that are dependent on mechanical ventilation and have intact phrenic nerves.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year from date of enrollment</time_frame>
      <desc>No details to include</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death while device was not in use</sub_title>
                <description>Two of the deaths occurred while the patient was being mechanically ventilated and not paced. In one case the patient was found lifeless during the night; in another case the patient died of cardiac arrhythmia and subsequent cardiac failure.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Death while device was in use</sub_title>
                <description>One patient was observed to lose consciousness while the device was functioning. A second patient died of septic shock due to urosepsis and was using the device prior to a hypotensive arrest. No device malfunction was observed.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Elevated Temperature</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Acute Polynephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood from and around treacheostomy tube</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Temperature</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain/Discomfort no device use</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain/discomfort with stimulation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Broken External Wire</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>External Equipment Failure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Broken Anode</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>without evidence of respiratory distress, hypoxemia or aspiration</description>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Increased secretions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Low oxygen saturation/tidal volume</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Capnothorax</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>Includes Cold/Nasal Congestion</description>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pressure Sore</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Thompson</name_or_title>
      <organization>Synapse Biomedical, Inc.</organization>
      <phone>440-774-2488 ext 121</phone>
      <email>jthompson@synapsebiomedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

